Showing results (1241-1250 of 5,224) with videos related to
Sort By:
Pageof 523
Antiviral Research|June 25, 2026
Ginsenoside Rb2-based inactivation enables a Zika vaccine that maintains pregnancy and protects offspring against virusHanlin Chen, Tong Wu, Liangming Chen, et al.Antiviral Research|April 23, 2013
Control and prevention of canine rabies: the need for building laboratory-based surveillance capacityAshley C Banyard, Daniel L Horton, Conrad Freuling, et al.Antiviral Research|December 3, 2014
Animal models of viral hemorrhagic feverDarci R Smith, Michael R Holbrook, Brian B GowenAntiviral Research|January 1, 1993
Treatment of lethal Pichinde virus infections in weanling LVG/Lak hamsters with ribavirin, ribamidine, selenazofurin, and ampligenD F Smee, J Gilbert, J A Leonhardt, et al.Antiviral Research|April 30, 2019
Structural and pharmacological evaluation of a novel non-nucleoside reverse transcriptase inhibitor as a promising long acting nanoformulation for treating HIVShalley N Kudalkar, Irfan Ullah, Nicole Bertoletti, et al.Antiviral Research|September 26, 2020
Characterization of hepatitis B virus surface antigen particles expressed in stably transformed mammalian cell lines containing the large, middle and small surface proteinJuan Manuel Battagliotti, Diego Fontana, Marina Etcheverrigaray, et al.Antiviral Research|December 24, 2022
Current status of silica-based nanoparticles as therapeutics and its potential as therapies against virusesDanny Jian Hang Tng, Jenny Guek Hong LowAntiviral Research|June 19, 2015
Irbesartan, an FDA approved drug for hypertension and diabetic nephropathy, is a potent inhibitor for hepatitis B virus entry by disturbing Na(+)-dependent taurocholate cotransporting polypeptide activityXue-jun Wang, Wei Hu, Ting-yu Zhang, et al.Antiviral Research|April 13, 2026
NSUN2-mediated RNA m5C Dysregulation Links HBV Infection to TFEB Silencing and Lysosomal ImpairmentXuejiao Dong, Shuang Ding, Lili He, et al.Antiviral Research|August 9, 2026
Porcine Serum Amyloid A2 Blocks PRRSV by Directly Targeting Virion-Associated PIP2 and GP5Shuai Li, Yuanxiang Xiong, Liurong Fang, et al.Pageof 523